How to handle use of additional medication for Alzheimer’s Disease during randomised clinical trials?

Claus Dethlefsen, Peter Johannsen · 2025

Read How to handle use of additional medication for Alzheimer’s Disease during randomised clinical trials? by Claus Dethlefsen, Peter Johannsen (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11712364.txt.

Description

Claus Dethlefsen and Peter Johannsen write a methods paper on extra medication use inside Alzheimer's drug trials in a 2025 piece. Phase three trials run over eighteen months, and participants often start standard symptom drugs along the way. That extra use can blur the trial's main result, making the tested drug look better or worse than it is.

Guidelines disagree: one major trial paper backs counting all outcomes as they come, while the European regulator backs imagining outcomes without the extra drug. The authors propose a middle path using the estimand framework. The extra drug counts as an event with both a start and a stop date. Only readings taken while it could act are swapped for the imagined scenario. They say this sharpens what a trial result means.

Catalog record

CREATORClaus Dethlefsen, Peter Johannsen
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE2 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC11712364

Browse the full library · About the Tower of Babel